放射性复发前列腺癌的挽救性前列腺近距离放疗:一项国际德尔菲共识研究
该国际德尔菲共识研究邀请34名专家参与三轮改良德尔菲法,就挽救性前列腺近距离放疗的患者选择、技术类型和随访等形成共识。56%(18/32)的声明达成共识,包括初始放疗后至少2-3年、应行MRI和PSMA PET、应行靶向和系统活检;最大T分期/PSA、ADT使用、寡转移联合SABR及重复挽救性BT未达共识。多数意见倾向于高剂量率挽救性BT,局灶和全腺体技术均可适用,无单一首选剂量/分割方案。
要点
- 共识建议初始放疗后至少2-3年再行挽救性前列腺近距离放疗。
- 共识建议行MRI和PSMA PET检查,并行靶向和系统活检。
- 多数意见倾向于高剂量率挽救性BT,局灶和全腺体技术均可适用。
核心结论
- 该德尔菲研究达成的共识领域可为挽救性前列腺近距离放疗提供实用建议。
- 未来挽救性BT的研究应解决本研究识别的争议领域。
研究设计与样本
- 邀请34名挽救性前列腺BT国际专家参与三轮改良德尔菲技术。
- 问题聚焦患者和癌症特异性标准、BT类型和技术以及随访。
- 预设共识阈值为≥75%,多数意见为≥50%。
主要发现
- 30名国际专家同意参与,56%(18/32)的声明达成共识。
- 患者选择共识包括:初始RT至挽救性BT至少2-3年;应行MRI和PSMA PET;应行靶向和系统活检。
- 未达共识领域包括:挽救时最大T分期/PSA;ADT的使用/持续时间;局部挽救联合SABR用于寡转移疾病的适宜性;重复第二疗程挽救性BT。
- 多数意见倾向于高剂量率挽救性BT,并指出局灶和全腺体技术均可适用。
- 无单一首选剂量/分割方案。
关键数值与推荐
- 共识阈值预设为≥75%,多数意见为≥50%。
- 共识声明:初始RT至挽救性BT至少2-3年。
- 共识声明:应行MRI和PSMA PET。
- 共识声明:应行靶向和系统活检。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Local recurrences after previous radiotherapy (RT) are increasingly being identified in biochemically recurrent prostate cancer. Salvage prostate brachytherapy (BT) is an effective and well tolerated treatment option. We sought to generate international consensus statements on the use and preferred technical considerations for salvage prostate BT. MATERIALS AND METHODS: International experts in salvage prostate BT were invited (n = 34) to participate. A three-round modified Delphi technique was utilized, with questions focused on patient- and cancer-specific criteria, type and technique of BT, and follow-up. An a priori threshold for consensus of ≥ 75% was set, with a majority opinion being ≥ 50%. RESULTS: Thirty international experts agreed to participate. Consensus was achieved for 56% (18/32) of statements. Consensus was achieved in several areas of patient selection: 1) A minimum of 2-3 years from initial RT to salvage BT; 2) MRI and PSMA PET should be obtained; and 3) Both targeted and systematic biopsies should be performed. Several areas did not reach consensus: 1) Maximum T stage/PSA at time of salvage; 2) Utilization/duration of ADT; 3) Appropriateness of combining local salvage with SABR for oligometastatic disease and 4) Repeating a second course of salvage BT. A majority opinion preferred High Dose-Rate salvage BT, and indicated that both focal and whole gland techniques could be appropriate. There was no single preferred dose/fractionation. CONCLUSION: Areas of consensus within our Delphi study may serve as practical advice for salvage prostate BT. Future research in salvage BT should address areas of controversy identified in our study.
引用
- Corkum MT, Buyyounouski MK, Chang AJ, et al. Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study. Radiother Oncol. 2023. PMID: 37059334. doi:10.1016/j.radonc.2023.109672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。